SG149069A1 - Seneca valley virus based compositions and methods for treating disease - Google Patents

Seneca valley virus based compositions and methods for treating disease

Info

Publication number
SG149069A1
SG149069A1 SG200809634-9A SG2008096349A SG149069A1 SG 149069 A1 SG149069 A1 SG 149069A1 SG 2008096349 A SG2008096349 A SG 2008096349A SG 149069 A1 SG149069 A1 SG 149069A1
Authority
SG
Singapore
Prior art keywords
svv
nucleic acids
provides methods
proteins
methods
Prior art date
Application number
SG200809634-9A
Other languages
English (en)
Inventor
Paul L Hallenbeck
Carl M Hay
Shanthi Ganesh
Seshidar Reddy Police
Ling Xu
Jingping Yang
Cheng Cheng
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG149069A1 publication Critical patent/SG149069A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32061—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG200809634-9A 2003-09-26 2004-09-23 Seneca valley virus based compositions and methods for treating disease SG149069A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50618203P 2003-09-26 2003-09-26

Publications (1)

Publication Number Publication Date
SG149069A1 true SG149069A1 (en) 2009-01-29

Family

ID=34393123

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200809634-9A SG149069A1 (en) 2003-09-26 2004-09-23 Seneca valley virus based compositions and methods for treating disease

Country Status (12)

Country Link
EP (1) EP1668025B1 (enExample)
JP (1) JP2007506434A (enExample)
KR (1) KR20060103890A (enExample)
CN (1) CN1875028B (enExample)
AU (1) AU2004275832A1 (enExample)
BR (1) BRPI0414810A (enExample)
CA (1) CA2540177A1 (enExample)
DK (1) DK1668025T3 (enExample)
IL (1) IL174430A0 (enExample)
MX (1) MXPA06003318A (enExample)
SG (1) SG149069A1 (enExample)
WO (1) WO2005030139A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US7638318B2 (en) 2003-09-26 2009-12-29 Norvartis Ag Seneca Valley virus based compositions and methods for treating disease
WO2007047256A2 (en) * 2005-10-13 2007-04-26 Neotropix, Inc. Svv-based animal vaccines and uses thereof
WO2017096201A1 (en) 2015-12-02 2017-06-08 Memorial Sloan-Kettering Cancer Center Seneca valley virus (svv) cellular receptor targeted oncotherapy
CN105925728B (zh) * 2016-06-01 2019-09-20 华南农业大学 一种塞内加谷病毒实时荧光定量pcr检测引物及试剂盒
US10323069B2 (en) * 2016-08-23 2019-06-18 Regents Of The University Of Minnesota Senecavirus A antigens and methods of use
RU2020106730A (ru) * 2017-07-14 2021-08-16 Онкорус, Инк. Инкапсулированные полинуклеотиды и способы их применения
CN109627293B (zh) * 2017-08-13 2021-02-09 中牧实业股份有限公司 塞尼卡谷病毒结构蛋白抗原表位多肽及其应用
CN107513524B (zh) * 2017-09-30 2021-02-09 中牧实业股份有限公司 一株猪塞内加谷病毒毒株及其应用
CN108467904B (zh) * 2018-05-24 2021-11-19 华南农业大学 检测塞尼卡谷病毒的rt-lamp引物组、试剂盒及应用
CN109182278B (zh) * 2018-10-12 2021-08-06 河南省动物疫病预防控制中心 塞尼卡谷病毒毒株及其应用
CA3117924A1 (en) * 2018-11-13 2020-05-22 Oncorus, Inc. Encapsulated polynucleotides and methods of use
CN109234464A (zh) * 2018-11-23 2019-01-18 山东新希望六和集团有限公司 用于检测塞尼卡谷病毒的引物及探针、荧光定量pcr试剂盒及方法和应用
CN111733144A (zh) * 2019-03-25 2020-10-02 金宇保灵生物药品有限公司 一种塞内卡病毒的纯化方法及病毒液的浓缩纯化方法
CN110229218B (zh) * 2019-06-24 2020-12-01 中国动物疫病预防控制中心(农业农村部屠宰技术中心) 检测塞内卡病毒抗体的试剂及其所用多肽
WO2021016194A1 (en) * 2019-07-19 2021-01-28 Racaniello Vincent R Second generation seneca valley virus oncolytic therapy: compositions and methods thereof
CN110923211A (zh) * 2019-12-25 2020-03-27 哈药集团生物疫苗有限公司 塞内卡病毒分离株、塞内卡病毒病灭活疫苗及其制备方法
CN111286491A (zh) * 2020-02-03 2020-06-16 河南省动物疫病预防控制中心 猪塞内卡病毒核酸标准物及其应用
CN111849925B (zh) * 2020-07-06 2022-06-03 马忠仁 一种抗结肠癌疫苗及其制法
CN111798712B (zh) * 2020-07-15 2021-10-29 周晓庆 噬菌体侵染细菌3d智能模拟方法
CN111944764A (zh) * 2020-08-31 2020-11-17 信阳农林学院 一种表达猪塞内加谷病毒蛋白的细胞系、构建方法和应用
CN112390861A (zh) * 2020-09-30 2021-02-23 信阳农林学院 表达猪塞内加谷病毒vp1蛋白的细胞系、构建方法和应用
CN117281824B (zh) * 2023-08-11 2025-10-21 华南农业大学 Trim基因的过表达剂在制备抑制猪塞内卡病毒复制的产品中的应用
CN117487006B (zh) * 2023-12-29 2024-04-12 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 一种抗a型塞内卡病毒的单克隆抗体以及抗原表位及应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia

Also Published As

Publication number Publication date
KR20060103890A (ko) 2006-10-04
HK1094583A1 (en) 2007-04-04
BRPI0414810A (pt) 2006-11-14
JP2007506434A (ja) 2007-03-22
WO2005030139A2 (en) 2005-04-07
CN1875028B (zh) 2012-07-04
EP1668025A4 (en) 2007-05-16
AU2004275832A1 (en) 2005-04-07
EP1668025A2 (en) 2006-06-14
IL174430A0 (en) 2006-08-01
CA2540177A1 (en) 2005-04-07
CN1875028A (zh) 2006-12-06
WO2005030139A3 (en) 2005-10-20
MXPA06003318A (es) 2006-06-08
DK1668025T3 (da) 2014-08-25
EP1668025B1 (en) 2014-06-25

Similar Documents

Publication Publication Date Title
WO2005030139A3 (en) Seneca valley virus based compositions and methods for treating disease
WO2006101841A3 (en) Seneca valley virus based compositions and methods for treating disease
Perrault et al. Absence of transcriptase activity or transcription-inhibiting ability in defective interfering particles of vesicular stomatitis virus
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
WO2002101075A9 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
GB2397062A (en) RNA interference mediated inhibition of hepatitis c virus (HCV) gene expression using short interfering nucleic acid (siNA)
EP1124846A4 (en) NUCLEOTID AND PROTEIN SEQUENCES OF NOGO GENES AND METHODS BASED ON THEM
EP1322338A4 (en) COMPOSITIONS AND METHODS FOR USE OF THE CAPSID PROTEIN FROM FLAVIVIRES OR PESTVIRUSES
PT1404347E (pt) Nucleosidos 4'-substituidos para o tratamento de doencas mediadas pelo virus da hepatite c
EP1623046A4 (en) Compositions and methods for treating severe acute respiratory syndrome (SARS)
CA2413190A1 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
DE602004029651D1 (de) Verwendung von artemisinin zur behandlung von durch onkogene viren gebildeten tumoren und zur behandlung von viralen infektionen
DE60132190D1 (de) Mutierte version der arginin deiminase
WO2002064839A3 (en) Methods for the diagnosis and treatment of tumors employing the hepsin gene
BR0107912A (pt) Composto, composições, e, métodos para tratar ou prevenir o c ncer ou doença neoplástica, método para inibir o desenvolvimento de uma célula cancerìgena ou célula neoplástica, método para tratar ou prevenir uma infecção viral em um paciente, e para inibir a replicação ou a infectividade de um vìrus
WO2007109668A3 (en) Compositions and methods for improving bone mass through modulation of novel receptors of pth and fragments thereof
WO2003044161A3 (en) Gene amplification and overexpression in cancer
WO2023205689A3 (en) Deoptimized influenza viruses and methods of treating cancer
IL207012A (en) 28sgp medicinal product and 28sgp accent cancer treatment vaccine
WO2005005632A3 (fr) PETITS ARN INTERFERENTS SPECIFIQUES DES SOUS-UNITES α, α' ET β DE LA PROTEINE KINASE CK2 ET LEURS APPLICATIONS
WO2005121169A3 (en) Apoptosis-inducing polypeptides
DE60023891D1 (de) Peptidverbindung, die von einem verschobenen offenen leserahmen des ice-gens abstammt
WO2000069455A3 (de) Organ-, gewebs- und zellspezifisches immuntherapeutikum für chronische virale infektionen, sowie entzündliche, degenerative und proliferative erkrankungen insbesondere der leber sowie krebs auf der basis von rekombinantem parapoxvirus
ATE397673T1 (de) Verstärktes krebs-gen wip1
WO2002085305A3 (en) Compositions and methods for inducing cancer cell death